Trial Outcomes & Findings for Efficacy of TAP Block in Cesarean Section Patients (NCT NCT03493828)

NCT ID: NCT03493828

Last Updated: 2018-11-13

Results Overview

The total the number of Patient Controlled Analgesia (PCA) boluses used by the patients postoperatively within 24 hours

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

60 participants

Primary outcome timeframe

0-24 hours

Results posted on

2018-11-13

Participant Flow

Participant milestones

Participant milestones
Measure
TAP Using Bupivacaine 0.5%
TAP block using Bupivacaine 0.5%: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
TAP Using Bupivacaine 0.25%
TAP block using Bupivacaine 0.25%: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
Placebo
TAP block using Normal Saline: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
Overall Study
STARTED
20
20
20
Overall Study
COMPLETED
20
20
20
Overall Study
NOT COMPLETED
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=20 Participants
TAP block using Normal Saline: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
Total
n=60 Participants
Total of all reporting groups
TAP Using Bupivacaine 0.5%
n=20 Participants
TAP block using Bupivacaine 0.5%: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
TAP Using Bupivacaine 0.25%
n=20 Participants
TAP block using Bupivacaine 0.25%: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
Age, Categorical
<=18 years
0 Participants
n=20 Participants
0 Participants
n=60 Participants
0 Participants
n=20 Participants
0 Participants
n=20 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
n=20 Participants
60 Participants
n=60 Participants
20 Participants
n=20 Participants
20 Participants
n=20 Participants
Age, Categorical
>=65 years
0 Participants
n=20 Participants
0 Participants
n=60 Participants
0 Participants
n=20 Participants
0 Participants
n=20 Participants
Age, Continuous
32.5 years
n=20 Participants
33 years
n=60 Participants
33 years
n=20 Participants
34.5 years
n=20 Participants
Sex: Female, Male
Female
20 Participants
n=20 Participants
60 Participants
n=60 Participants
20 Participants
n=20 Participants
20 Participants
n=20 Participants
Sex: Female, Male
Male
0 Participants
n=20 Participants
0 Participants
n=60 Participants
0 Participants
n=20 Participants
0 Participants
n=20 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
North America
20 participants
n=20 Participants
60 participants
n=60 Participants
20 participants
n=20 Participants
20 participants
n=20 Participants

PRIMARY outcome

Timeframe: 0-24 hours

Population: Number of PCA bolus used within 24 hours

The total the number of Patient Controlled Analgesia (PCA) boluses used by the patients postoperatively within 24 hours

Outcome measures

Outcome measures
Measure
TAP Using Bupivacaine 0.5%
n=20 Participants
TAP block using Bupivacaine 0.5%: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
TAP Using Bupivacaine 0.25%
n=20 Participants
TAP block using Bupivacaine 0.25%: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
Placebo
n=20 Participants
TAP block using Normal Saline: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
Effect of Transversus Abdominis Plane (TAP) Block Using Either 0.5% or 0.25% Bupivacaine on Analgesia for Cesarean Section Patients When Compared to Placebo.
9.45 PCA bolus
Standard Error 1.292
8.95 PCA bolus
Standard Error 1.756
17.65 PCA bolus
Standard Error 2.893

Adverse Events

TAP Using Bupivacaine 0.5%

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

TAP Using Bupivacaine 0.25%

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr Joel Yarmush

New York Methodist Hospital

Phone: (718) 780-3279

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place